Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of oral LDK378 in adults with ALK-abnormal tumors
NL-OMON36240Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceritinib in solid tumor, non-small cell lung cancer (NSCLC), neuroblastoma and 1 more, sponsored by Novartis. Primary endpoint: Incidence rate of dose-limiting toxicities. Started May 2011; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)neuroblastomainflammatory pseudotumor (IPT)
Beyond the preview
Go deeper on NL-OMON36240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36240.